- Home
- STRO vs IMMX Comparison
STRO vs IMMX Comparison
Compare STRO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- IMMX
- Stock Information
- Founded
- STRO 2003
- IMMX 2014
- Country
- STRO United States
- IMMX United States
- Employees
- STRO N/A
- IMMX N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- STRO Health Care
- IMMX Health Care
- Exchange
- STRO Nasdaq
- IMMX Nasdaq
- Market Cap
- STRO 74.3M
- IMMX 65.5M
- IPO Year
- STRO 2018
- IMMX 2021
- Fundamental
- Price
- STRO $0.89
- IMMX $2.08
- Analyst Decision
- STRO Hold
- IMMX Strong Buy
- Analyst Count
- STRO 7
- IMMX 1
- Target Price
- STRO $1.97
- IMMX $8.00
- AVG Volume (30 Days)
- STRO 598.8K
- IMMX 182.4K
- Earning Date
- STRO 11-12-2025
- IMMX 11-11-2025
- Dividend Yield
- STRO N/A
- IMMX N/A
- EPS Growth
- STRO N/A
- IMMX N/A
- EPS
- STRO N/A
- IMMX N/A
- Revenue
- STRO $104,473,000.00
- IMMX N/A
- Revenue This Year
- STRO $65.42
- IMMX N/A
- Revenue Next Year
- STRO N/A
- IMMX N/A
- P/E Ratio
- STRO N/A
- IMMX N/A
- Revenue Growth
- STRO N/A
- IMMX N/A
- 52 Week Low
- STRO $0.52
- IMMX $1.26
- 52 Week High
- STRO $4.80
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- STRO 48.52
- IMMX 41.50
- Support Level
- STRO $0.85
- IMMX $2.09
- Resistance Level
- STRO $1.01
- IMMX $2.34
- Average True Range (ATR)
- STRO 0.09
- IMMX 0.15
- MACD
- STRO -0.01
- IMMX 0.01
- Stochastic Oscillator
- STRO 16.57
- IMMX 30.77
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.